Blue Pool Capital — 2018 Investments

2 investments dated 2018 · listed companies and verified rows first · show all

Brii Biosciencesbriibio.com inMay 2018

Hong Kong-listed (2137.HK) biotech founded in 2018 developing infectious disease therapies, led by hepatitis B functional-cure programs.

Zhi Hong(Founder)in

Co-investorsARCH Venture Partners 6 Dimensions Capital Boyu Capital Sequoia Capital

Hua Medicinehuamedicine.comMar 2018 · $117.4M

Shanghai-based, HKEX-listed drug developer commercializing dorzagliatin, the first approved glucokinase activator for type 2 diabetes.

Li Chen(Founder)

Co-investorsARCH Venture Partners F-Prime Capital Venrock 6 Dimensions Capital Ally Bridge Group Eight Roads Ventures +2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.